Výsledky vyhledávání

Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial)

Autor: S. Ramalingam, J. Crawford, A. Chang, C. Manegold, R. Perez-Soler, J.-Y. Douillard, N. Thatcher, F. Barlesi, T. Owonikoko, Y. Wang, P. Pultar, J. Zhu, R. Malik, G. Giaccone, S. Della-Fiorentina, S. Begbie, R. Jennens, J. Dass, K. Pittman, N. Ivanova, T. Koynova, P. Petrov, A. Tomova, V. Tzekova, F. Couture, V. Hirsh, R. Burkes, R. Sangha, M. Ambrus, T. Janaskova, J. Musil, J. Novotny, P. Zatloukal, J. Jakesova, K. Klenha, J. Roubec, J. Vanasek, J. Fayette, J. Bennouna-Louridi, C. Chouaid, J. Mazières, H. Vallerand, G. Robinet, P.-J. Souquet, D. Spaeth, R. Schott, H. Lena, Y. Martinet, C. El Kouri, N. Baize, A. Scherpereel, O. Molinier, F. Fuchs, K.M. Josten, N. Marschner, F. Schneller, T. Overbeck, M. Thomas, J. von Pawel, M. Reck, W. Schuette, V. Hagen, C.-P. Schneider, V. Georgoulias, I. Varthalitis, K. Zarogoulidis, K. Syrigos, C. Papandreou, C. Bocskei, E. Csanky, E. Juhasz, G. Losonczy, Z. Mark, I. Molnar, Z. Papai-Szekely, S. Tehenes, I. Vinkler, S. Almel, A. Bakshi, S. Bondarde, A. Maru, A. Pathak, R.M. Pedapenki, K. Prasad, S.V.S.S. Prasad, N. Kilara, D. Gorijavolu, C.D. Deshmukh, S. John, L.M. Sharma, D. Amoroso, E. Bajetta, P. Bidoli, A. Bonetti, F. De Marinis, M. Maio, R. Passalacqua, S. Cascinu, A. Bearz, M. Bitina, A. Brize, G. Purkalne, M. Skrodele, A.A. Baba, K. Ratnavelu, M.H. Saw, M.C. Samson-Fernando, G.E. Ladrera, J. Jassem, P. Koralewski, P. Serwatowski, M. Krzakowski, C. Cebotaru, D. Filip, D.E. Ganea-Motan, C.H. Ianuli, I.G. Manolescu, A. Udrea, O. Burdaeva, M. Byakhov, A. Filippov, S. Lazarev, I. Mosin, S. Orlov, D. Udovitsa, A. Khorinko, S. Protsenko, H.L. Lim, Y.O. Tan, E.H. Tan, R. Bastus Piulats, J. Garcia-Foncillas, J. Valdivia, J. de Castro, M. Domine Gomez, S.W. Kim, J.-S. Lee, H.K. Kim, J.S. Lee, S.W. Shin, D.-W. Kim, Y.-C. Kim, K.C. Park, C.-S. Chang, G.-C. Chang, Y.-G. Goan, W.-C. Su, C.-M. Tsai, H.-P. Kuo, M. Benekli, G. Demir, E. Gokmen, A. Sevinc, M. Haigentz, M. Agarwal, S. Pandit, R. Araujo, N. Vrindavanam, P. Bonomi, A. Berg, J. Wade, R. Bloom, B. Amin, R. Camidge, D. Hill, M. Rarick, P. Flynn, L. Klein, K. Lo Russo, M. Neubauer, P. Richards, R. Ruxer, M. Savin, D. Weckstein, R. Rosenberg, T. Whittaker, D. Richards, W. Berry, C. Ottensmeier, A. Dangoor, N. Steele, Y. Summers, E. Rankin, K. Rowley, S. Giridharan, H. Kristeleit, C. Humber, P. Taylor

Publikováno v: Annals of Oncology. 24:2875-2880

Background Talactoferrin alfa is an oral dendritic cell (DC)-mediated immunotherapy (DCMI). We tested whether talactoferrin was superior to placebo in advanced non-small-cell lung cancer (NSCLC). Patients and methods An FORTIS-M trial was an internat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::279f128904fe8fc09b31972c2bf65519
https://doi.org/10.1093/annonc/mdt371

Zobrazit plný text záznamu

A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin's disease

Autor: T, Hahn, M, Benekli, C, Wong, K B, Moysich, A, Hyland, A M, Michalek, A, Alam, M R, Baer, B, Bambach, M S, Czuczman, M, Wetzler, J L, Becker, P L, McCarthy

Publikováno v: Bone Marrow Transplantation. 35:557-566

There are several prognostic models for Hodgkin's disease (HD) patients, but none evaluating patient characteristics at time of blood and marrow transplantation (BMT). We developed a prognostic model for event-free survival (EFS) post-BMT based on HD

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41f1bbb77fe98375afc48c919aedce56
https://doi.org/10.1038/sj.bmt.1704789

Zobrazit plný text záznamu

Burden of Metastatic Castration-Resistant Prostate Cancer (MCRPC) in Turkey

Autor: F Dane, C Sar, Ergun Oksuz, Simten Malhan, TS Sozen, Levent Kabasakal, B Kahveci, M Benekli, C Cag, O Kucuk, E Erdal

Publikováno v: Value in Health. 19:A725-A726

WOS: 000396606302380

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2eea094240f8c274618ad0701f7f4c96
https://doi.org/10.1016/j.jval.2016.09.2170

Zobrazit plný text záznamu

Multiple primary malignant neoplasms: multi-center results from Turkey

Autor: N A, Babacan, S, Aksoy, B, Cetin, N Y, Ozdemir, M, Benekli, U, Uyeturk, M, Ali Kaplan, T, Kos, H, Karaca, B, Oksuzoglu, N, Zengin, S, Buyukberber

Publikováno v: Journal of B.U.ON. : official journal of the Balkan Union of Oncology. 17(4)

Multiple primary malignant neoplasms (MPMNs) are defined as a diagnosis of two or more indepen-dent primary malignancies of different histologies/origins in an individual. The frequency of MPMN is being increasing. In this study we aimed to determine

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::17598054c7e3bc77472b829cd8f68cc0
https://pubmed.ncbi.nlm.nih.gov/23335539

Zobrazit plný text záznamu

Trabectedin in advanced soft tissue sarcoma: case series

Autor: U, Demirci, S, Buyukberber, T, Yetisyigit, O, Dizdar, M, Benekli, N, Alkis, U, Coskun

Publikováno v: Journal of B.U.ON. : official journal of the Balkan Union of Oncology. 17(3)

The prognosis of advanced soft tissue sarcomas (STS) is poor. The median overall survival (OS) is 6 months in unresectable and metastatic STS that progress after treatment with anthracyclines and ifosfamide. Trabectedin is an alkylating agent, effect

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::2c74a23b9253b3e86da1e4e18cb47a87
https://pubmed.ncbi.nlm.nih.gov/23033305

Zobrazit plný text záznamu

Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cisplatin: retrospective analysis of a multicenter study

Publikováno v: Journal of B.U.ON. : official journal of the Balkan Union of Oncology. 17(1)

The majority of patients with pancreatic cancer present with advanced disease. Systemic chemotherapy for patients with pancreatic cancer has limited impact on overall survival (OS). Patients eligible for chemotherapy should be selected carefully. The

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::ab41e0495ae834caadaf1decb64be113
https://pubmed.ncbi.nlm.nih.gov/22517701

Zobrazit plný text záznamu

Efficacy and toxicity of preoperative chemotherapy with docetaxel and epirubicin in locally advanced invasive breast cancer

Autor: A O, Kaya, U, Coskun, S, Buyukberber, M, Benekli, E, Tekin, C, Cifter, B, Ozturk, R, Yildiz, E, Yaman, A, Uner, D, Yamac

Publikováno v: Journal of B.U.ON. : official journal of the Balkan Union of Oncology. 15(2)

To investigate the efficacy and safety of neoadjuvant chemotherapy with docetaxel plus epirubicin with granulocyte colony-stimulating factor (G-CSF) support in locally advanced breast cancer patients.We retrospectively evaluated the records of 39 pat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::092a30cbafc0f41af535a23911eff11d
https://pubmed.ncbi.nlm.nih.gov/20658717

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání